NCT07520760 2026-04-09
MBC-EA
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
9 trialsNCT07455019 2026-03-06
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07443397 2026-03-02
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT03016819 2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3 Recruiting
NCT07419932 2026-02-19
NeoLATC
Fujian Medical University
Recruiting
NCT07396454 2026-02-09
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07398326 2026-02-09
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Shanghai Changzheng Hospital
Phase 2 Recruiting
NCT06662006 2026-02-06
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small MoleculeĀ±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT07359053 2026-01-22
MAGNATE-S
Shanghai 6th People's Hospital
Phase 2 Recruiting